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Abstract Pharmacogenomics is the science about how
inherited factors influence the effects of drugs. Drug
response is always a result of mutually interacting genes
with important modifications from environmental and
constitutional factors. Based on the genetic variability of
pharmacokinetic and in some cases pharmacodynamic
variability we mention possible implications for the acute
and preventive treatment of migraine. Pharmacogenomics
will most likely in the future be one part of our therapeutic
armamentarium and will provide a stronger scientific basis
for optimizing drug therapy on the basis of each patient’s
genetic constitution.
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Introduction
The human genome consists of approximately three billion
base pairs, and the number of coding sequences (‘‘genes’’)
ranges from 20 to 25,000 [1]. Single nucleotide polymor-
phisms or SNPs (pronounced ‘‘snips’’) are DNA sequence
variations that occur when a single nucleotide (A, T, C, or
G) in the genome sequence is altered in at least 1% of the
population. SNPs, which make up about 90% of all human
genetic variation, occur every 100–300 bases along the
3-billion-base human genome. SNPs can occur in both
coding (gene) and noncoding regions of the genome. Many
SNPs have no effect on cell function, but some could
predispose people to disease or influence their response to a
drug. Pharmacogenomics is the science about how inher-
ited factors influence the effects of drugs [2]. It is a new
science about how the systematic identification of all the
human genes, their products, interindividual variation,
intraindividual variation in expression and function over
time may be used both to predict the right treatment in
individual patients and to design new drugs.
Drug response is always to some extent determined by
genetic factors. It is never determined by a single gene
alone or by a group of genes. Drug response is always a
result of mutually interacting genes with important modi-
fications from environmental and constitutional factors.
Genotyping before treatment is of possible value if drug
response mainly is determined by a single or just a few
genes characterized for all clinically relevant SNPs, and
when all clinically relevant environmental and constitu-
tional influences are known and measurable both when
treatment is initiated and during treatment.
The classical phenotype definition of genetic polymor-
phism is a phenotypic trait that exists in the population in at
least two phenotypes (and presumably in at least two
genotypes) the rarest of whom exist in say 1% of the
population.
In the past, pharmacogenetics mostly dealt with genetic
polymorphism in drug metabolism. The main enzyme
system responsible for drug metabolism is the cytochrome
P450 (CYP) enzyme system. In humans there are 57 CYP
genes and 33 pseudogenes. They are organized into 18
families and 42 subfamilies. The CYP enzymes that
metabolize drugs belong to families 1, 2 and 3.
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The pharmacogenomic research ultimately aims of
developing better and safer drugs and/or better and safer
use of currently available drugs.
Migraine can be regarded as an episodic–chronic dis-
order [3] and in the treatment of migraine one should
consider treatment of the migraine attacks and in many
cases also preventive treatment. Therefore the possible
implications of pharmacogenomics will be dealt with in the
following separately for acute and preventive migraine
treatment. In each of these sections the possible pharma-
cokinetic and pharmacodynamic implications will be
described.
Very little has been achieved until the recent demon-
stration in cluster headache that the response to triptans is
related to polymorphism in the G protein b3 [4].
In 2001 it was stated: as migraine has been demonstrated
to have a strong, but complex, genetic component, phar-
macogenetics bears great promise in providing new targets
for drug development and optimization of individual spe-
cific therapy [5]. Better, preferably prophylactic, treatment
of migraine patients is desired because the drugs now used
are not effective in all patients, allow recurrence of the
headache in a high percentage of patients and sometimes
have severe adverse events [5].
Acute migraine treatment
The anti-migraine, specific triptans, 5-HT1B/1D receptor
agonists, are generally regarded, as very effective acute
migraine drugs [6]. This fact, however, is not always evi-
dent in current randomised clinical trials with oral triptans
[7–9]. One could argue that this is so because only the most
severely afflicted patients participate in these randomised
clinical trials. However, in migraine patients with infre-
quent attacks recruited by general practitioners and by
advertisement the results are quite similar [10].
It was recently stated that many patients have no
response to triptans and complete pain relief is the excep-
tion rather than the rule [11]. How high is then the
maximum effect of triptans? After subcutaneous naratrip-
tan 10 mg the pain-free response was 87% [12, 13]. Hence,
with parenteral naratriptan one gets near the maximum for
pain-free.
Pharmacogenomics and pharmacokinetics
Eletriptan is metabolised by CYP3A4 and the oral bio-
availability (OBA) is 50%. Sumatriptan (OBA 14%),
rizatriptan (OBA 40%), almotriptan (OBA 80%) are all
metabolised by monoamine oxidase (MAO)-A [9, 14, 15].
Zolmitriptan (OBA 39%) is metabolised by CYP 1A2 and
the active metabolite 183C91 by MAO-A [16]. Naratriptan
(OBA 74%) is excreted by the kidney and metabolism
represents only a minor route of elimination of the
drug [17].
The Cmax after oral 200 mg sumatriptan varied from 52
to 227 ng/ml in healthy volunteers [18]. In migraine
patients outside attacks the 2 h plasma levels of zolmi-
triptan varied from 3 to 27 ng/ml and during attacks the
plasma levels varied from 0 to 15 ng/ml after zolmitriptan
10 mg [19]. Such large variability in plasma levels sug-
gests heterogeneity in the metabolism in the liver most
likely due to heterogeneity of MOA-A and CYP1A2.
Clinical comments
Ideally, one could try whether the migraine patient respond
to subcutaneous sumatriptan 6 mg, the currently most
effective available treatment [8, 9]. If the patient respond to
subcutaneous sumatriptan one could then because can be
inconvenient and because of the high cost of the subcuta-
neous sumatriptan (35 Euro per injection) try oral
administration of a triptan. In theory genotyping of the
patient may be useful, if the patient is not responding, and
depending on the triptan in question it could in theory be
genotyping of MAO-A, CYP 1A2 and CYP3A4 (see
above). However, genotyping for these three enzymes is
not relevant in clinical practice because the prediction of
the phenotype is poor.
A CGRP antagonist BIBN079BS was effective when
given intravenously [11] and CGRP antagonists are now
being developed for oral use. The CGRP antagonist
MK-0974 300 mg (68%) was superior to placebo (46%) for
headache relief in a phase II study [20]. The pharmacoki-
netic profile of MK-0974 and variability of its metabolic
pass way is currently unknown.
Pharmacogenomics and pharmacodynamics
Freedom of pain after 2 h is the currently suggested pri-
mary efficacy parameter in randomised, clinical trials in
migraine [21]. Treatment with an oral triptan results in
pain-free responses from 30 to 40% of the patients in
randomised, clinical trials when the headaches are mod-
erate or severe [7]. When the migraine attacks are treated in
the mild phase of headache the 2 h pain-free responder rate
increases considerably. Thus, the pain-free response was
43% after zolmitriptan 2.5 mg [22], 51–66% after suma-
triptan 50–100 mg [23, 24], and 70% after rizatriptan
10 mg [25].
For subcutaneous naratripan the dose-response curve
was established in one early study in the development
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programme of the drug, see Fig. 1 [12]. The mere fact that
a dose-response could be established in this relatively small
study (n = 34–69 per dose) and that a high maximum
response of 87% (95% confidence intervals: 78–93%)[12,
13] was found suggest homogeneity in the pharmacody-
namic response to naratriptan.
The pain-free response was lower for sumatriptan: -
33% (95% confidence intervals: -15 to -51%) [12]. The
high maximum effect for naratriptan 10 mg, 87% pain-free
[12], could be inherent to this drug because it is 2–3 times
more potent than sumatriptan at the 5-HT1B/1D receptor in
some animal models relevant to migraine [26, 27] but, at
present, this remains a matter of speculation.
The CGRP receptor on human middle meningeal artery
is CGRP (1) [28]. There is no information about possible
genetic heterogeneity of this receptor in man. In coronary
arteries there is heterogeneity of the CGRP receptor CGRP
(1), CGRP (2) and unknown [29].
One large study in cluster headache was recently pub-
lished [4]. In 231 cluster headache patients the GNB3
genotype and allele frequency were indistinguishable from
other cross-sectional German samples [4]. A total of 180
patients used a triptan, of whom 71% reported treatment
success. The adjusted odds ratio for treatment response to
triptans for heterozygotous carriers of the GNB3 825T
allele was 2.96 (95% confidence interval 1.34–6.56;
P = 0.0074) versus carriers of the 825CC genotype [4].
The C825TC polymorphism had a positive predictive value
for triptan response of 0.82 and a negative predictive value
of 0.35. The C825T polymorphism has been associated
with an enhanced signal transduction via G protein-coupled
receptors [4]. The same polymorphism has been associated
with hypertension [30, 31], with the response to
antidepressant [32] and with the venous response to
nitroglycerin [33].
In another study with same patient population it was
found that the G1246A polymorphism in the hypocretin
receptor 2 gene was not associated with treatment response
[34].
Previously, no evidence for involvement of the 5-HT1F
receptor gene in the response to sumatriptan in migraine
patients was found [35]. Similarly, in the same migraine
patient population there was no association of drug
response and 5-HT1B receptor polymorphism [36]. A
recent study found no evidence that variants F124C and
A-161T of the 5-HT receptor are major determinants in the
clinical response to sumatriptan [37]. One recent study
suggested that the DRD2/NcoI allele may be considered a
susceptibility factor heralding a good response to oral
rizatriptan [38].
Clinical comments
The results for G protein b3 polymorphism in cluster
headache [4] should be investigated in migraine patients. If
there is an association between the response in migraine
patients to triptans and the polymorphism then genotyping
for this gene will be an option in the future.
There is heterogeneity of the 5-HT1B receptor but this
was not linked to treatment response
Preventive migraine treatment
The majority of drugs currently used in migraine preven-
tion were not developed for migraine prophylaxis [39–42].
The serotonin antagonists methysergide and pizotifen were
developed 40–50 years ago for migraine prophylaxis [43].
Preventive drugs for migraine, beta-blockers, serotonin
antagonists, calcium blockers, antiepileptics, NSAIDs, and
antidepressants, are not universally effective. The respon-
der rates (a 50% decrease in incidence) range from 40 to
50% [39–42, 44]. Ideally, preventive treatment should
results in no or one attack per month [43] but this cannot be
obtained with current unspecific therapy. In the future, one
can hope that migraine specific preventive therapy will be
developed.
Pharmacogenetics and pharmacokinetics
The two beta-blockers propranolol and metoprolol have very
varied pharmacokinetics, in both cases most likely due to
differences in the first-passage effect and metabolic excre-

































Fig. 1 Pain-free response after 2 h for placebo (n = 63), and
subcutaneous naratriptan (Na) (0.5 mg (n = 69), 1 mg (n = 55),
2.5 mg (n = 42), 5 mg (n = 34), 10 mg (n = 34), and sumatriptam
6 mg (n = 47) [12]
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considerable, for example in essential tremor: 60–800 mg
propranolol daily [45]. In migraine the recommended doses
are 40–320 mg propranolol and 50–200 mg metoprolol [39].
Propranolol is highly lipophilic and it is well absorbed.
Most of the drug is metabolized by the liver during its first
passage through the portal circulation resulting in 25% oral
bioavailability [39]. There is great interindividual variation
in the presystemic clearance of propranolol resulting in
enormous variability in plasma concentration after oral
administration of the drug (approximately 20-fold). Pro-
pranolol is extensively metabolized and one of the products
of hepatic metabolism is 4-hydroxypropranolol, which
posses some b-blocking effect.
Propranolol is metabolised mainly by the P450 isozyme
CYP1A2 [46]. CYP1A2 displays considerable interindi-
vidual variability, and this is due mainly to genetic factors
[46]. So far no SNP or haplotype in the CYP1A2 has yet
been identified that can unequivocally be used to predict
the metabolic phenotype in any individual patient [47].
CYP1A2 and CYP2D6 hydroxylate propranolol and they
exhibit racial differences [48]. The genotype responsible
for the more than 60-fold interindividual differences in
human hepatic CYP1A2 constitutive expression is not
known [47]. There is a racial difference in the expression
of CYP1A2 [49].
Metoprolol is well absorbed but there is considerable
first-pass metabolism resulting in about 40% oral bio-
availability [40]. Plasma-concentrations of the drug vary
widely (up to 17-fold). Metoprolol is metabolised by
CYP2D6 and there is a 30-fold difference between the
highest and lowest clearance values [50] and a 30-fold
variability in AUC for the extensive metabolisers of
metoprolol [51]. For CYP2D6 there is genetic polymor-
phism with autosomal recessive heritage. Seven percent of
white Caucasians and 1–2% of Blacks and Orientals [39,
52] do not express this enzyme and are ‘‘poor metabolis-
ers’’. There is a pronounced allelic heterogeneity:
approximately 80 known variants, mainly in the form of
single nucleotide polymorphisms’s. CYP2D6*3, *4 and *5
together predict about 90% of poor metabolisers [53].
Results in cardiovascular patients suggested that phar-
macogenomic measures could be used to design more
individualized metoprolol dosage regimen for patients [50].
In hypertensive patients, however, there was no association
between variable pharmacokinetics or CYP2D6 genotypes
and beta-blocker-induced adverse events or efficacy [51].
Topiramate is not extensively predominately metabo-
lised and 50% is excreted by the kidneys as unmetabolised
drug [54]. Valproate is metabolised in the liver mainly by
glucuronidation but also by oxidation by several CYP [54].
The calcium entry blocker flunarizine is metabolised by
CYP2D [55]. Methysergide is a prodrug and is metabolised
with demethylation in the liver during the first-passage to
an active metabolite methylergometrine [56]. After oral
administration the AUC is 10 times greater for methyler-
gometrine than for methysergide [56]. Amitriptyline is
metabolised by N-demethylation by to nortiptyline by
CYP2C19, CYP1A2 and CYP3A4 [53].
Clinical comments
Preventive treatment in migraine is generally started with
low doses that are then, if necessary, increased over weeks
or months [39], the ‘‘start low go slow’’ dictum. With
genotyping of relevant metabolic enzymes one can proba-
bly in an advance design more individualized drug dosage
regimen for patients. Whether such regimens results in
better treatment depends on whether there is an association
between plasma levels and drug response. So far, this has
only been investigated in a small (n = 17) open study for
propranolol where no correlation was found [57].
For valproate determination of plasma levels is a routine
and one normally tend to titrate the dose to the levels used
in epilepsy.
Amitriptyline is N-demethylated to nortriptyline via
CYP1A2, CYP2C19 and CYP3A4 and 10-hydroxylated by
CYP2D6 [53]. All four enzymes are under genetic control,
but there is not a single genotype test, which predicts the
plasma levels of amitriptyline and nortriptyline.
Pharmacogenomics and pharmacodynamics
A variety of genetic and nongenetic factors determine b1-
blocker response [58]. Besides inherited differences in the
metabolism and disposition of drugs, gene polymorphisms
in the targets of drug therapy, for example receptors, can
have a significant influence on the efficacy and toxicity of
medications [59]. As mentioned above, there was no
association between variable pharmacokinetics or CYP2D6
genotypes and beta-blocker-induced adverse events or
efficacy [51]. In contrast, polymorphisms of the b1-adre-
noceptor determined the response to metoprolol in
hypertension in two studies [58, 59].
The mode of action of b-blockers in migraine is
unknown but is most likely via an effect on the brain,
probably on the central catecholaminergic system, as
indicated by the effect of b-blockers on contingent negative
variation in migraineurs [39, 60].
Clinical comments
If the effect of b-blockers in migraine is exerted by an
effect on the b1-receptor genotyping for this receptor could
16 J Headache Pain (2008) 9:13–18
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possibly in advance predict responders and nonresponders
confer the results in hypertension [58, 59].
For the other preventive medications in migraine, sero-
tonin antagonists, calcium entry blockers, antiepileptic
drugs, antidepressants, their mode of action in migraine is
unknown [40–43] and one can thus not for the moment
suggest what genes one should type in order to predict
response.
Final comments
Until now attempts to use pharmacogenomics in migraine
have been few and most have fail. In the future this will be
different. Pharmacogenomics will most likely in the future
be one part of our therapeutic armamentarium. Before use
of medication we will in some cases ask for genotyping of
relevant pharmacokinetic or pharmacodynamic genotypes
and then tailor the drug regimen to the individual patient.
The need for genotyping is most likely greatest in pre-
ventive treatment also in order to minimize the adverse
events, which frequently occur with this treatment [39–42,
44]. Pharmacogenomics will thus provide a stronger sci-
entific basis for optimizing drug therapy on the basis of
each patient’s genetic constitution [61] and will be an
integral determination of drug therapy [2]. This is most
likely to be the case when new migraine-specific, better
preventive drugs based on knowledge of the pathophysi-
ology of migraine have been developed.
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